BMC Cancer (Sep 2020)

Myxoid stroma is associated with postoperative relapse in patients with stage II colon cancer

  • Takashi Okuyama,
  • Shinichi Sameshima,
  • Emiko Takeshita,
  • Takashi Mitsui,
  • Takuji Noro,
  • Yuko Ono,
  • Tamaki Noie,
  • Shinichi Ban,
  • Masatoshi Oya

DOI
https://doi.org/10.1186/s12885-020-07335-w
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background Fibrosis surrounding cancer cells has been shown to affect cancer cell metastatic behavior. The present study aimed to explore the utility of myxoid stroma as a predictive factor for postoperative relapse in patients with stage II colon cancer. Methods The present study retrospectively investigated 169 patients who underwent curative surgical resection of stage II colon cancer. The fibrotic stroma was classified according to Ueno’s criteria, and the patients were divided into the myxoid (MY) group and the non-MY (NMY) group. We also recorded tumor budding (TB) and investigated the combination of MY and TB for postoperative relapse. Postoperative survival was also explored. Results Thirty-two (18.9%) patients had MY. MY was significantly associated with tumor budding (TB) and postoperative relapse (p < 0.001 and p < 0.001, respectively). The 5-year RFS rates in MY group and NMY group were 52.1 and 94.6% (p < 0.0001), and the 5-year OS rates in MY group and NMY group were 74.6 and 93.3% (p = 0.001). Multivariate analysis showed that both MY and TB were significant risk factors for postoperative relapse (p < 0.001 and p = 0.02, respectively), and that only TB was a significant risk factor for OS (p = 0.043). Furthermore, compared with patients with either one of MY or TB, patients with both MY and TB had postoperative relapse more frequently (11.4% vs. 53.8%). Conclusions The present study suggests that MY is a predictive marker for postoperative relapse in patients with stage II colon cancer.

Keywords